We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$1B
Turnover
3.6%
1-Year Est. Return
50.12%
This Fund
S&P 500
This Quarter
Est. Return
+9.43%
1 Year Est. Return
+50.12%
3 Year Est. Return
+144.24%
5 Year Est. Return
+295.18%
10 Year Est. Return
+883.61%
AUM
$1.25B
AUM Growth
-$22.5M
(-1.8%)
Cap. Flow
-$64.1M
Cap. Flow
% of AUM
-5.13%
Top 10 Holdings %
Top 10 Hldgs %
36.19%
Holding
463
New
112
Increased
98
Reduced
115
Closed
63
Avg Time Held
1.4
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ovintiv
OVV
|
+$27.3M |
| 2 |
Antero Resources
AR
|
+$14.4M |
| 3 |
Home Depot
HD
|
+$9.11M |
| 4 |
Fox Class A
FOXA
|
+$8.62M |
| 5 |
Danaos Corp
DAC
|
+$5.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
EQT Corp
EQT
|
+$59.4M |
| 2 |
Coterra Energy
CTRA
|
+$20.4M |
| 3 |
Devon Energy
DVN
|
+$19.7M |
| 4 |
ING
ING
|
+$19M |
| 5 |
Stellantis
STLA
|
+$12.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 33.98% |
| 2 | Technology | 11.6% |
| 3 | Healthcare | 11.04% |
| 4 | Industrials | 10.23% |
| 5 | Consumer Discretionary | 9.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
Medtronic
MDT
$121B
| $1.61M | 0.13% |
14,531
-3,376
| -19% | -$357K |
2013 Q2
35 quarters
|
|
127
Portillo's
PTLO
$339M
| $1.59M | 0.13% |
64,691
+28,403
| +78% | +$752K |
2021 Q4
1 quarter
|
|
128
CDW
CDW
$18.8B
| $1.59M | 0.13% |
8,874
-1,873
| -17% | -$343K |
2014 Q2
31 quarters
|
|
129
Hercules Capital
HTGC
$3.07B
| $1.58M | 0.13% |
87,263
-7,831
| -8% | -$138K |
2013 Q4
33 quarters
|
|
130
Vicor
VICR
$9.15B
| $1.57M | 0.13% |
22,201
-26,158
| -54% | -$2.35M |
2019 Q4
9 quarters
|
|
131
Warby Parker
WRBY
$3.01B
| $1.56M | 0.13% |
46,185
+32,971
| +250% | +$1.07M |
2021 Q4
1 quarter
|
|
132
DELISTED
Agiliti Inc
AGTI
| $1.55M | 0.12% |
73,469
-71,440
| -49% | -$1.35M |
2021 Q2
3 quarters
|
|
133
Custom Truck One Source
CTOS
$2.07B
| $1.53M | 0.12% |
182,727
+80,726
| +79% | +$652K |
2021 Q3
2 quarters
|
|
134
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.53M | 0.12% |
+43,591
| New | +$1.27M |
2022 Q1
0 quarters
|
|
135
American Express
AXP
$212B
| $1.52M | 0.12% |
8,120
-3,337
| -29% | -$603K |
2013 Q2
35 quarters
|
|
136
Lam Research
LRCX
$337B
| $1.5M | 0.12% |
28,000
-280
| -1% | -$16.3K |
2019 Q3
10 quarters
|
|
137
DELISTED
H&E Equipment Services
HEES
| $1.5M | 0.12% |
34,443
-2,090
| -6% | -$87.9K |
2021 Q4
1 quarter
|
|
138
DELISTED
Integral Acquisition Corporation 1 Class A Common Stock
INTE
| $1.5M | 0.12% |
151,180
| – | – |
2021 Q4
1 quarter
|
|
139
DELISTED
Cantaloupe
CTLP
| $1.49M | 0.12% |
220,000
| – | – |
2021 Q2
3 quarters
|
|
140
Vanguard FTSE Developed Markets ETF
VEA
$228B
| $1.48M | 0.12% |
30,809
| – | – |
2018 Q3
14 quarters
|
|
141
JPMorgan Chase
JPM
$900B
| $1.48M | 0.12% |
10,849
-2,828
| -21% | -$417K |
2013 Q2
35 quarters
|
|
142
Cleveland-Cliffs
CLF
$6.94B
| $1.48M | 0.12% |
+45,800
| New | +$1.04M |
2022 Q1
0 quarters
|
|
143
Luxfer Holdings
LXFR
$466M
| $1.47M | 0.12% |
87,715
+26,375
| +43% | +$467K |
2021 Q1
4 quarters
|
|
144
Abbott
ABT
$181B
| $1.47M | 0.12% |
12,415
-2,800
| -18% | -$347K |
2020 Q3
6 quarters
|
|
145
Cytokinetics
CYTK
$8.64B
| $1.46M | 0.12% |
39,732
-3,086
| -7% | -$110K |
2021 Q3
2 quarters
|
|
146
AEON Biopharma
AEON
$11.9M
| $1.46M | 0.12% |
2,066
| – | – |
2021 Q2
3 quarters
|
|
147
FS KKR Capital
FSK
$2.86B
| $1.45M | 0.12% |
63,586
-4,195
| -6% | -$93K |
2014 Q2
31 quarters
|
|
148
Illinois Tool Works
ITW
$77.6B
| $1.45M | 0.12% |
6,917
-11
| -0.2% | -$2.46K |
2021 Q1
4 quarters
|
|
149
Sixth Street Specialty
TSLX
$1.63B
| $1.44M | 0.12% |
61,888
-3,428
| -5% | -$80.3K |
2014 Q2
31 quarters
|
|
150
PIMCO Corporate & Income Strategy Fund
PCN
$805M
| $1.42M | 0.11% |
90,000
| – | – |
2013 Q2
35 quarters
|
|
Similar funds
HWM
FAM
KL
BWP
LOIM
AWP
BDWCC
MVIP
Advisory Research's Q1 2022 Portfolio in Review
As of Q1 2022, Advisory Research held 463 positions worth $1.25B, down 1.8% from $1.27B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Advisory Research withdrew a net $64.1M in Q1 2022, closing 63 positions and reducing 115 holdings. Its most notable exit was EQT Corp, an estimated $59.4M position sold in full.
By sector, the portfolio is most concentrated in Energy at 34% of assets, up from 31% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Advisory Research opened a new position in Ovintiv worth $34.2M.
- Advisory Research's largest Q1 2022 buy was Ovintiv: 633,386 shares worth $34.2M.
- Advisory Research added most to Antero Resources in Q1 2022, an estimated $14.4M increase.
- Advisory Research's biggest Q1 2022 reduction was Coterra Energy, cutting an estimated $20.4M.
- Advisory Research fully exited EQT Corp in Q1 2022, selling an estimated $59.4M.
- Advisory Research's ten largest holdings make up 36% of its $1.25B portfolio in Q1 2022.
- Advisory Research opened 112 new positions and closed 63 in Q1 2022.
- Advisory Research's portfolio value fell 1.8% quarter-over-quarter to $1.25B.
Based on Advisory Research's 13F filing for Q1 2022, filed 16 May 2022.